Atherothrombosis and the Metabolic Syndrome

The Metabolic Syndrome

Volumn , Issue , 2006, Pages 163-187

  Dunn, Emma J ^a   Grant, Peter J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

'Syndrome X'; Association of metabolic and pro thrombotic factors; Atherothrombosis and metabolic syndrome; Insulin resistance and endothelial dysfunction; Insulin resistance and haemostatic system; Metabolic syndrome insulin resistance syndrome; Platelets and metabolic syndrome

Indexed keywords

EID: 84856067387     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470025131.ch6     Document Type: Chapter

References (159)

1. Albrink, M., Krauss, R., Lindgren, F., Von der Groeben, V., Wood, P. 1980. Intercorrelations among high density lipoproteins, obesity, and triglycerides in a normal population. Lipids, 15, 668-678.
2. Alessi, M., Peiretti, F., Morange, P., Henry, M., Nalbone, G., Juhan-Vague, I. 1997. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes, 46, 860-867.
3. Anfossi, G., Mularoni, E., Burzacca, S., Ponziani, M., Massucco, P., Mattiello, L., Cavalot, F., Trovati, M. 1998. Platelet resistance to nitrates in obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care, 21, 121-126.
4. Arbini, A., Bauer, K. 1994. Reduced plasma factor VII coagulant activity due to the Arg353Gln polymorphism in the factor VII gene results from defective secretion (abstract). Blood, 86, 86.
5. Asplund-Carlson, A., Hamsten, A., Wiman, B., Carlson, L. 1993. Relationship between plasma plasminogen activator inhibitor-1 and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo-and hypertriglyceridaemic men. Diabetologia, 36, 817-825.
6. Aznar, J., Estelles, A., Tormo, G., Sapena, P., Tormo, V., Blanch, S., Espana, F. 1988. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br. Heart J., 59, 535-541.
7. Baldi, S., Natali, A., Buzzigoli, G., Gavlan, A., Sironi, A., Ferrannini, E. 1996. In vitro effect of insulin on intracellular calcium concentrations: relation to insulin resistance. Metabolism, 45, 1402-1407.
8. Balleisen, L., Assmann, G., Bailey, J., Epping, P., Schulte, H., van de Loo, J. 1985a. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population-I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using, and menopause. Thromb. Haemost., 54, 475-479.
9. Balleisen, L., Assmann, G., Bailey, J., Epping, P., Schulte, H., van de Loo, J. 1985b. Epidemiological Study on factor VII, factor VIII and fibrinogen in an industrial population-II. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb. Haemost, 54, 721-723.
10. Balletshofer, B., Rittig, K., Enderle, M., Volk, A., Maerker, E., Jacob, S., Matthaei, S., Rett, K., Haring, H. 2000. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation, 101, 1780-1784.
11. Bastard, J., Pieroni, L., Hainque, B. 2000. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab. Res. Rev., 16, 192-201.
12. Betteridge, D., El Tahir, K., Reckless, J., Williams, K. 1982. Platelets from diabetic subjects show diminished sensitivity to prostacycline. Eur. J. Clin. Invest., 12, 395-398.
13. Bini, A., Fenoglio, J., Sobel, J., Owen, J., Fejgl, M., Kaplan, K. 1987. Immunohistochemical characterization of fibrinogen, fibrin I, and fibrin II in human thrombi and atherosclerotic lesions. Blood., 69, 1038-1045.
14. Bini, A., Fenoglio, J., Mesa-Tejada, R., Kudryk, B., Kaplan, K. 1989. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Arteriosclerosis, 9, 109-121.
15. Blann, A. 1991. Increased circulating levels of von Willebrand Factor antigen in smokers may be due to lipid peroxides. Med. Sci. Res., 19, 535-536.
16. Blann, A., Naqvi, T., Waite, M., McCollum, C. 1993. Von Willebrand factor and endothelial damage in essential hypertension. J. Hum. Hypertens., 7, 107-111.
17. Bonithon-Kopp, C., Scarabin, P.-Y., Bara, L., Castanier, N., Jacqueson, A., Roger, M. 1988. Relationship between sex hormones and haemostatic factors in healthy middle-aged men. Atherosclerosis, 71, 71-76.
18. Brook, R., Bard, R., Glazewski, L., Kehrer, C., Bodary, P., Eitzman, D., Rajagopalan, S. 2004. Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. Am. J. Cardiol., 93, 1012-1016.
19. Bruckert, E., de Sousa, J., Giral, P., Soria, C., Chapman, M., Caen, J., de Gennes, J. 1989. Interrelationship of plasma triglyceride and coagulant factor VII levels in normotriglycer-idemic hypercholesterolaemia. Atherosclerosis, 75, 129-134.
20. Calles-Escandon, J., Mirza, S., Sobel, B., Schneider, D. 1998. Induction of hyperinsulinaemia combined with hyperglycaemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes, 47, 290-293.
21. Camus, J. 1966. Goutte, diabete, hyperlipidime: un trisyndrome metabolique. Rev. Rheumat., 33, 10-14.
22. Carter, A., Catto, A., Grant, P. 1998. Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease. Thromb. Haemost., 80, 632-636.
23. Carvalho, A., Lees, R., Vaillancourt, R., Cabral, R., Colman, R. 1978. Activation of the kallikrein system in hyperbetalipoproteinemia. J. Lab. Clin. Med., 91, 117-122.
24. Carvalho de Sousa, J., Soria, C., Ayrault-Jarrier, M., Pastier, D., Bruckert, E., Amiral, J., Bereziat, G., Caen, J. 1988. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J. Clin. Pathol., 41, 940-944.
25. Carvalho de Sousa, J., Bruckert, E., Giral, P., Soria, C., Chapman, J., Truffert, J., Dairou, F., de Gennes, J., Caen, J. 1989. Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity. Haemostasis, 19, 125-130.
26. Chandler, W., Alessi, M., Aillaud, M., Henderson, P., Vague, P., Juhan-Vague, I. 1997. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type-1(PAI-1) complex. Circulation, 96, 761-768.
27. G-monomethyl-L-arginine of vasodilator effects of acetylcholine and metacholine in human foreman in human forearm vasculature. Br. J. Pharmacol., 110, 736-738.
28. Conlan, M., Folsom, A., Finch, A., Davis, C., Sorlie, P., Marucci, G., Wu, K. 1993. Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities Study. Thromb. Haemost., 70, 380-385.
29. Corretti, M., Anderson, T., Benjamin, E., Celermajer, D., Charbonneau, F., Creager, M., Deanfield, J., Drexler, H., Gerhard-Herman, M., Herrington, D., Vallance, P., Vita, J., Vogel, R. 2002. Force IB ART: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol., 39, 257-265.
30. de Lange, M., Snieder, H., Ariens, R., Spector, T., Grant, P. 2001. The genetics of haemostasis: a twin study. Lancet, 357, 101-105.
31. de Lange, M., Snieder, H., Ariens, R., Andrew, T., Grant, P., Spector, T. 2003. The relation between insulin resistance and hemostasis: pleiotropic genes and common environment. Twin Res., 6, 1-10.
32. DeWood, M., Spores, J., Notske, R., Mouser, L., Burroughs, R., Golden, M., Lang, H. 1980. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N. Engl. J. Med., 303, 897-902.
33. Dobrovolsky, A., Titaeva, E. 2002. The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Moscow), 67, 99-108.
34. Doolittle, R. 1984. Fibrinogen and fibrin. Annu. Rev. Biochem., 53, 195-229.
35. Dunn, E., Ariens, R., de Lange, M., Snieder, H., Turney, J., Spector, T., Grant, P. 2004. Genetics of fibrin clot structure: a twin study. Blood, 103, 1735-1740.
36. Egeberg, O. 1962. Clotting factor levels in patients with coronary atherosclerosis. Scand. J. Clin. Lab. Invest., 14, 253-258.
37. Erikkson, P., Kallin, B., Hooft, V., Bavenholm, P., Hamsten, A. 1995. Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. USA, 92, 1851-1855.
38. Ernst, E., Resch, K. 1993. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann. Intern. Med., 118, 956-963.
39. Fatah, K., Silveira, A., Tornvall, P., Karpe, F., Blomback, M., Hamsten, A. 1996. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb. Haemost., 76, 535-540.
40. Festa, A., D'Agostino, R., Mykkanen, L., Tracy, R., Zaccaro, D., Hales, C., Haffner, S. 1999. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler. Thromb. Vasc. Biol., 19, 562-568.
41. Festa, A., D'Agostino, R., Tracy, R., Haffner, S. 2002. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes, 51, 1131-1137.
42. Folsom, A., Wu, K., Davis, C., Conlan, M., Sorlie, P., Szklo, M. 1991. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis, 91, 191-205.
43. Folsom, A., Wu, K., Rosamund, W., Sharrett, A., Chambless, L. 1997. Prospective study of Hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 96, 1102-1108.
44. Gabriel, D., Muga, K., Boothroyd, E. 1992. The effect of fibrin structure on fibrinolysis. J. Biol. Chem, 267, 24259-24263.
45. Grant, P., Kruithof, E., Felley, C., Felber, J., Bachmann, F. 1990. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor 1 concentrations in man. Clin. Sci., 79, 513-516.
46. Green, D., Ruth, K., Folsom, A., Liu, K. 1994. Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler. Thromb., 14, 686-693.
47. Green, F., Kellener, C., Wilkes, H., Temple, A., Meade, T., Humphries, S. 1991. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler. Thromb., 11, 540-546.
48. Gris, J., Schved, J., Aguilar-Martinez, P., Arnaud, A., Sanchez, N. 1990. Impact of physical training on plasminogen activator inhibitor activity in sedentary men. Fibrinolysis, 4, 97-98.
49. Gryglewski, R., Botting, R., Vane, J. 1988. Mediators produced by the endothelial cell. Hypertension, 12, 530-548.
50. Haffner, S., 2003. Insulin resistance, inflammation, and the prediabetic state. Am. J. Cardiol., 92, 18j-26j.
51. Haffner, S., Stern, M., Hazuda, H., Mitchell, B., Patterson, J. 1988. Increased insulin concentrations in nondiabetic offspring of diabetic patients. N. Engl. J. Med, 319, 1297-1301.
52. Haffner, S., Stern, M., Hazuda, H., Mitchell, B., Patterson, J. 1989. Parential history of diabetes is associated with increased cardiovascular risk factors. Arteriosclerosis, 9, 928-933.
53. Hajek, A., Joist, J., Baker, R., Jarrett, L. 1979. Demonstration and partial characterization of insulin receptors in human platelets. J. Clin. Invest., 63, 1060-1065.
54. Halcox, J., Schenke, W., Zalos, G., Mincemoyer, R., Prasad, A., Waclawiw, M., Nour, K., Quyyumi, A. 2002. Prognostic value of coronary vascular endothelial dysfunction. Circulation, 106, 653-658.
55. Hamdy, O., Ledbury, S., Mullooly, C., Jarema, C., Porter, S., Ovalle, K., Moussa, A., Caselli, A., Caballero, A., Economides, P., Veves, A., Horton, E. 2003. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care, 26, 2119-2125.
56. Hamsten, A., Defaire, U., Wallidus, G., Dahlen, G., Szamosi, A., Landov, C., Blomback, M., Wiman, B. 1987. Plasminogen activator inhibitor in plasma: a risk factor for recurrent myocardial infarction. Lancet, ii, 3-9.
57. Hansen, B. 1999. The metabolic syndrome X. Ann. NY Acad. Sci., 892, 1-24.
58. Heinrich, J., Balleisen, L., Schulte, H. G. A., van de Loo, J. 1994. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler. Thromb., 14, 54-59.
59. Heywood, D., Mansfield, M., Grant, P. 1996. Factor VII gene polymorphisms, factor VII;c levels and features of insulin resistance in non-insulin dependent diabetes mellitus. Thromb. Haemost., 75, 401-406.
60. Hsueh, W., Quinones, M. 2003. Role of endothelial dysfunction in insulin resistance. Am. J. Cardiol, 92 (Suppl.), 10J-17J.
61. Huisveld, I., Leenen, R., van de Kooy, K., Hospers, J., Seidell, J., Deurenberg, P., Koppeschaar, H., Mosterd, W., Boupma, B. 1990. Body composition and weight reduction in relation to antigen and activity of plasminogen activator inhibitor (PAI-1) in overweight individuals. Fibrinolysis, 4, 84-85.
62. Humphries, S., Lane, A., Green, F., Cooper, J., Miller, G. 1994. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arterioscler. Thromb., 14, 193-198.
63. Ishibashi, K., Kageyama, S., Sakurai, T., Murakawa, Y., Aihara, K., Yokota, K., Taniguchi, I., Hashimoto, Y., Fujita, T., Tajima, N. 1997. Inhibitory effects of insulin on intracellular calcium and aggregatory response of platelets are impaired in hypertensive subjects with insulin resistance. Hypertens. Res., 20, 225-231.
64. Jansson, J., Nilsson, T., Johnson, O. 1991. Von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br. Heart. J., 66, 351-355.
65. Juhan-Vague, I., Thompson, S., Jespersen, J. 1993. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Arterioscler. Thromb, 13, 1865-1873.
66. Juhan-Vague, I., Vague, P., Alessi, M., Badier, C., Valadier, J., Aillaud, M., Atlan, C. 1987. Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diab. Metab., 13, 331-336.
67. Juhan-Vague, I., Alessi, M., Joly, P., Thirion, W., Vague, P., Declerck, P., Serradimigni, A., Collen, D. 1989a. Plasma plasminogen activator inhibitor in angina pectoris. Influence of plasma insulin and acute phase response. Arteriosclerosis, 9, 362-367.
68. Juhan-Vague, I., Roul., C., Alessi, M., Ardissone, J., Heim, M., Vague, P. 1989b. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Thromb. Haemost., 61, 370-373.
69. Juhan-Vague, I., Pyke, S., Alessi, M., Jespersen, J., Haverkate, F., Thompson, S. 1996. Fibrinolytic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation, 94, 2057-2063.
70. Kadish, J. 1979. Fibrin and atherogenesis-a hypothesis. Atherosclerosis, 33, 409-413.
71. Kain, K., Catto, A., Grant, P. 2003. Associations between insulin resistance and thrombotic risk factors in high-risk South Asian subjects. Diab. Med., 20, 651-655.
72. Kario, K., Narita, N., Matsuo, T., Kayaba, K., Tsutsumi, A., Matsuo, M., Miyata, T., Shimada, K. 1995. Genetic determinants of plasma factor VII activity in the Japanese. Thromb. Haemost., 73, 617-622.
73. Katakam, P., Ujhelyi, M., Hoenig, M., Miller, A. 1998. Endothelial dysfunction precedes hypertension in diet induced insulin resistance. Am. J. Physiol., 275, R788-R792.
74. Koenig, W. 2003. Fibrin(ogen) in cardiovascular disease: an update. Thromb. Haemost., 89, 601-609.
75. Kohler, H., Carter, A., Stickland, M., Grant, P. 1998a. Levels of activated FXII in survivors of myocardial infarction-association with circulating risk factors and extent of coronary artery disease. Thromb. Haemost., 79, 14-18.
76. Kohler, H., Stickland, M., Ossei-Gerning, N., Carter, A., Grant, P. 1998b. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb. Haemost., 79, 8-13.
77. Kooistra, T., Bosma, P., Tons, H., van de Berg, A., Meyer, P., Princen, H. 1989. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb. Haemost., 62, 723-728.
78. Korsan-Bengtsen, K., Wilhelmsen, L., Tibblin, G. 1972. Blood coagulation and fibrinolysis in a random sample of 788 men 54 years old. Relations of the variables to 'risk factors' for myocardial infarction. Thromb. Diath. Haemorrh., 28, 99-108.
79. Krolewski, A., Czyzyk, A., Kopczynski, J., Rywik, S. 1981. Prevalence of diabetes mellitus, coronary heart disease and hypertension in the families of insulin dependent and insulin independent diabetes. Diabetologia, 21, 520-524.
80. Kroll, M., Schafer, A. 1989. Biochemical mechanisms of platelet activation. Blood, 74, 1181-1195.
81. Kruithof, E. 1988. Plasminogen activator inhibitor type 1: biochemical, biological and clinical aspects. Fibrinolysis, 2, 59-70.
82. Laine, H., Yki-Jarvinen, H., Kirvela, O., Tolvanen, T., Raitakari, M., Solin, O., Haaparanta, M., Knuuti, J., Nuutila, P. 1998. Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. J. Clin. Invest., 101, 1156-1162.
83. Landin, K., Tengborn, L., Smith, U. 1990. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J. Intern. Med., 227, 273-278.
84. Landin, K., Stigendal, L., Eriksson, E., Krotkiewski, M., Risberg, B. L. T., Smith, U. 1990. Abdominal obesity is associated with impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism, 39, 1044-1048.
85. Lind, S., Marks, P., Ewenstein, B. 2003. Hemostatic system. In Blood. Principles and Practice of Hematology (2nd edn), Handin, R., Lux, IV, S., Stossel, T. (eds). Lippincott Williams & Wilkins: Philadelphia, 2003; 959-982.
86. Lowe, G., Drummond, M., Third, J., Bremner, W., Forbes, C., Prentice, C., Lawrie, T. 1980. Increased plasma fibrinogen and platelet aggregates in type II hyperlipoproteinaemia. Thromb. Haemost., 42, 1503-1507.
87. Lusis, A. 2000. Atherosclerosis. Nature, 407, 233-241.
88. Mansfield, M., Strickland, M., Grant, P. 1995. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor 1 in caucasian patients with non insulin dependent diabetes mellitus. Thromb. Haemost., 74, 842-848.
89. Mansfield, M., Heywood, D., Grant, P. 1996. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first degree relatives of patients with NIDDM. Circulation, 94, 2171-2176.
90. Mansfield, M., Stickland, M., Grant, P. 1997. PAI-1 concentrations in first degree relatives of patients with non-insulin dependent diabetes: metabolic and genetic associations. Thromb. Haemost., 77, 357-361.
91. Mansfield, M., Kohler, H., Ariens, R., Grant, P. 2000. Circulating levels of coagulation factor XIII in subjects with type II diabetes and their first degree relatives. Diabetes Care, 23, 703-705.
92. Mark, A., Correia, M., Rahmouni, K., Haynes, W. 2002. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J. Hypertens., 20, 1245-1250.
93. McGill, J., Schneider, D., Arfken, C., Lucore, C., Sobel, B. 1994. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes, 43, 104-109.
94. McKeigue, P., Shah, B., Marmot, M. 1991. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet, 337, 382-386.
95. Meade, T., Chakrabarti, R., Haines, A., North, W. 1980. Haemostatic function and cardiovascular death: Early results of a prospective study. Lancet, 1, 1050-1054.
96. Meade, T., Mellows, S., Brozovic, M., Miller, G., Chakrabarti, R., North, W., Haimes, A., Stirling, Y., Imeson, J., Thompson, S. 1986. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet, 2, 533-537.
97. Meade, T., Ruddock, V., Stirling, Y., Chakrabarti, R., Miller, G. 1993. Fibrinolytic activity, clotting factors, and long term incidence of ischaemic heart disease in Northwick Park Heart Study. Lancet, 342, 1076-1079.
98. Meigs, J., Mittleman, M., Nathan, D., Tofler, G., Murphy-Sheehy, P., Lipinska, I., D'Agostino, R., Wilson, P. 2000. Hyperinsulinaemia, hyperglycaemia and impaired hemostasis. The Framingham Offspring Study. JAMA, 283, 221-228.
99. Meilahn, E., Ferrell, R., Kiss, J., Temple, A., Green, F., Humphries, S., Kuller, L. 1995. Genetic determination of coagulation factor VIIc levels among healthy middle-aged women. Thromb. Haemost., 73, 623-625.
100. Miller, G., Walter, S., Stirling, Y., Thompson, S., Esnouf, M., Meade, T. 1985. Assay of factor VII activity by two techniques: evidence for increased conversion of VII to VIIa in hyperlipidaemia, with possible implications for ischaemic heart disease. Br. J. Haematol., 59, 249-258.
101. Miller, G., Martin, J., Mitropoulos, K., Reeves, B., Thompson, R., Meade, T., Cooper, J., Cruickshank, J. 1991. Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition. Atherosclerosis, 86, 163-171.
102. Miller, G., Esnouf, M., Burgess, A., Cooper, J., Mitchell, J. 1997. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler. Thromb. Vasc. Biol, 17, 2103-2106.
103. Mitropoulos, K., Miller, G., Reeves, B., Wilkes, H., Cruickshank, J. 1988. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis, 76, 203-208.
104. Mussoni, L., Maderna, P., Camera, M., Bernini, F., Sironi, L., Sirtori, M., Tremoli, E. 1990. Atherogenic lipoproteins and PAI-1 releases by endothelial cells. Fibrinolysis, 4, 79-81.
105. Myreng, Y., Aurnes, I., Hjermann, I., Stormorken, H., Sund, T., Hellem, A. 1986. Von Willebrand factor and cardiovascular risk. Thromb. Res., 41, 867-871.
106. Nagy, J., Henricksson, P., McDonagh, J. 1986. Biosynthesis of factor XIII B subunit by human hepatoma cell lines. Blood, 68, 1272-1279.
107. Neel, J. 1962. Diabetes mellitus: a 'thrifty' genotype rendered detrimental by 'progress'? Am. J. Hum. Genet., 14, 353-362.
108. Nilsson, T., Boman, K., Bjerle, P., Hallmans, G., Hellsten, G. 1994. Von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J. Intern. Med, 235, 419-423.
109. Nilsson, L., Banfi, C., Diczfalusy, U., Tremoli, E., Hamsten, A., Erikkson, P. 1998. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler. Thromb. Vasc. Biol., 18, 1679-1685.
110. Nordt, T., Klassen, K., Schneider, D., Sobel, B. 1993. Augmentation of synthesis of plasma plasminogen activator inhibitor 1 in arterial cells by glucose and its implications for local fibrinolysis. Arterioscler. Thromb. Vasc. Biol., 13, 1822-1828.
111. Norman, B., Wallen, P., Ranby, M. 1985. Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transition. Eur. J. Biochem., 149, 193-200.
112. Ouchi, N., Kihara, S., Arita, Y., Maeda, K., Kuriyama, H., Okamoto, Y., Nishida, M., Takahashi, M., Nakamura, T., Yamashita, S., Funahashi, T., Matsuzawa, Y. 1999. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 100, 2473-2476.
113. Padayattay, S., Orme, S., Zenobi, P., Stickland, M., Belchetz, P., Grant, P. 1993. The effects of insulin-like growth factor-1 on plasminogen activator inhibitor 1 synthesis and secretion: results from in vitro and in vivo studies. Thromb. Haemost., 70, 1009-1013.
114. Paramo, J., Colucci, M., Collen, D., van der Werf, F. 1985. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. BMJ, 291, 575-576.
115. Pasqualini, L., Marchesi, S., Vaudo, G., Siepi, D., Angeli, F., Paris, L., Schillaci, G., Mannarino, E. 2003. Association between endothelial dysfunction and major cardiovascular events in peripheral vascular disease. Vasa, 32, 139-143.
116. Pedrinelli, R., Giampietro, O., Carmassi, F., Melillo, E., DelΓOmo, G., Catapano, G., Matteucci, E., Talarico, L., Morale, M., De Negri, F., Di Bello, V. 1994. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet, 344, 14-18.
117. Perticone, F., Caravolo, R., Candigliota, M., Ventura, G., Iacopino, S., Sinopoli, F., Mattioli, P. 2001. Obesity and Body Fat distribution induce endothelial dysfunction by oxidative stress. Protective effect of vitamin C. Diabetes, 50, 159-165.
118. Pinkney, J., Stehouwer, C., Coppack, S., Yudkin, J. 1997. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes, 46, s9-s13.
119. Raccah, D., Alessi, M., Scelles, V., Menard, C., Juhan-Vague, I., Vague, P. 1993. Plasminogen activator inhibitor activity in various types of endogenous hypertriglyceridaemia. Fibrinolysis, 7, 171-176.
120. Reaven, G. 1988. Role of insulin resistance in human disease. Diabetes, 37, 1595-1607.
121. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med., 340, 115-126.
122. Saha, N., Liu, Y., Heng, C., Hong, S., Low, P., Tay, J. 1994. Association of factor VII genotype with plasma factor VII activity and antigen levels in healthy Indian adults and interaction with triglycerides. Arterioscler. Thromb., 14, 1923-1927.
123. Sakkinen, P., Wahl, P., Cushman, M., Lewis, M., Tracy, R. 2000. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am. J. Epidemiol., 152, 897-907.
124. Saski, S., Higashi, Y., Nakagawa, K., Kimura, M., Noma, K., Hara, K., Matsuura, H., Goto, C., Oshima, T., Chayama, K. 2002. A low-calorie diet improves endothelium dependent vasodilatation in obese patients with essential hypertension. Am. J. Hypertens., 15, 302-309.
125. Sawdey, S., Loskutoff, D. 1991. Regulation of murine type 1 plasminogen activator inhibitor (PAI-1) gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor alpha and transforming growth factor beta. J. Clin. Invest., 88, 1346-1353.
126. Scarabin, P.-Y., Aillaud, M., Evans, A., Luc, G., Ferrieres, J., Arveiler, D., Juhan-Vague, I. 1998. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10500 male participants in a prospective study of myocardial infarction. The Prime Study. Thromb. Haemost., 80, 749-756.
127. Schmeling, A., Bockholdt, B., Schroder, H., Geserick, G. 1996. Phenotype change in polymorphic plasma proteins following liver transplantation. Exp. Clin. Immunogenet., 13, 78-83.
128. Schmitz-Huebner, U., Thompson, S., Balleisen, L., Fechtrup, C., Grosse-Heitmeyer, W., Kirchhof, B., Most, E., Muller, U., Seiffert, C., Seiffert, D., van de Loo, J. 1988. Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis. Br. Heart J., 59, 287-291.
129. Schneider, D. Sobel, B. 1996. Synergistic augmentation of expression of plasminogen activator inhibitor 1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron. Artery Dis., 7, 813-817.
130. Schneider, D., Absher, P., Ricci, M. 1997. Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor 1 by insulin on soluble factors released from vascular smooth muscle cells. Circulation, 96, 2868-2876.
131. Schwartz, M., Pizzo, S., Hill, R., McKee, P. 1973. Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J. Biol. Chem., 248, 1395-1407.
132. Seligsohn, U., Osterud, B., Brown, S., Griffin, J., Rapaport, S. 1979. Activation of human factor VII in plasma and purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J. Clin. Invest., 64, 1056-1065.
133. Simpson, H., Meade, T., Stirling, Y., Mann, J., Chakrabarti, R., Woolf, L. 1983. Hypertrig-lyceridaemia and hypercoagulability. Lancet, 1, 786-789.
134. Smith, E., Alexander, K., Massie, I. 1976. Insoluble 'fibrin' in human aortic intima. Quantitative studies on the relationship between insoluble 'fibrin', soluble fibrinogen and low density lipoprotein. Atherosclerosis, 23, 19-39.
135. Steinberg, H., Chaker, H., Learning, R., Johnson, A., Brechtel, G., Baron, A. 1996. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest., 97, 2601-2610.
136. Steinberg, H., Tarshoby, M., Monestel, R., Hook, G., Cronin, J., Johnson, A., Bayazeed, B., Baron, A. 1997. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilatation. J. Clin. Invest., 100, 1230-1239.
137. Steins, M., Padro, T., LI, C., Mesters, R., Ostermann, H., Hammel, D., Scheld, H., Berdel, W., Kienast, J. 1999. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis, 145, 173-180.
138. Stern, M. 1995. Diabetes and cardiovascular disease. The 'common soil' hypothesis. Diabetes, 44, 369-374.
139. Stewart, M., Humphriss, D., Berrish, T., Barriocanal, L., Trajano, L., Alberti, K., Walker, M. 1995. Features of syndrome X in first-degree relatives of NIDDM patients. Diabetes Care, 18, 1020-1022.
140. Sugrue, D., Trayner, I., Thompson, G., Vere, V., Imeson, J., Stirling, Y., Meade, T. 1985. Coronary artery disease and haemostatic variables in heterozygous familial hypercholes-terolaemia. Br. Heart J., 53, 265-268.
141. Sundell, I., Nilsson, T., Hallmans, G., Hellsten, G., Dahlen, G. 1989. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a North Swedish Population. Atherosclerosis, 80, 9-16.
142. Suwaidi, J., Hamasaki, S., Higano, S., Nishimura, R., Holmes, D. J., Lerman, A. 2000. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation, 101, 948-954.
143. Thompson, S., Kienast, J., Pyke, S., Haverkate, F., van de Loo, J. 1995. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N. Engl. J. Med, 332, 635-641.
144. Thompson, W., Smith, E. 1989. Atherosclerosis and the coagulation system. J. Pathol., 159, 97-106.
145. Trovati, M., Anfossi, G. 1998. Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured smooth muscle cells. Diabetologia, 41, 609-622.
146. Trovati, M., Anfossi, G. 2002. Influence of insulin and insulin resistance on platelet and vascular smooth muscle cell function. J. Diabetes Complic., 16, 35-40.
147. Vague, J. 1947. La differenciation sexulle, facteur determinant des formes de l' obesite. Presse Med., 55, 339-340.
148. Vague, P., Juhan-Vague, I., Aillaud, M., Badier, C., Viard, R., Alessi, M., Collen, D. 1986. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism, 35, 250-253.
149. Vague, P., Juhan-Vague, I., Alessi, M., Badier, C., Valadier, J. 1987. Metformin decreased the high plasminogen activator inhibitor capacity, plasma insulin and triglycerides in non diabetic obese subjects. Thromb. Haemost., 57, 326-328.
150. Vakkilainen, J., Makimattlia, S., Seppala-Lindroos, A., Vehkavaara, S., Lahdenpera, S., Groop, P., Taskinen, M., Yki-Jarvinen, H. 2000. Endothelial dysfunction in men with small LDL particles. Circulation, 102, 716-721.
151. Van Mejer, M., Pannehoek, H. 1995. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis, 9, 263-276.
152. Wagner, D. 1990. Cell biology of von Willebrand factor. Ann. Rev. Cell Biol., 6, 217-246.
153. Welborn, T., Breckenridge, A., Rubenstein, A., Dollery, C., Frasier, T. 1966. Serum insulin in essential hypertension and in peripheral vascular disease. Lancet, 1, 1336-1337.
154. Westerbacka, J., Yki-Jarvinen, H., Turpeinen, A., Rissanen, A., Vehkavaara, S., Syrjala, M., Lassila, R. 2002. Inhibition of platelet-collagen interaction. An in vivo action of insulin is abolished by insulin resistance in obesity. Arterioscler. Thromb. Vasc. Biol., 22, 167-172.
155. Wion, K., Kelly, D., Sunmmerfield, J., Tuddenham, E., Lawn, R. 1985. Distribution of factor VII mRNA and antigen in human liver and other tissues. Nature, 317, 726-729.
156. Yudkin, J., Stehouwer, C., Emeis, J., Coppack, S. 1999. C-Reactive protein in healthy subjects. Associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol., 19, 972-978.
157. Zack, P., Ischinger, T., Aker, U., Dincer, B., Kennedy, H. 1984. The occurrence of angio-graphically detected intracoronary thrombus in patients with unstable angina pectoris. Am. Heart. J, 108, 1408-1412.
158. Zahavi, J., Betteridge, J., Jones, N., Galton, D., Kakkar, V. 1981. Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidaemia. Am. J. Med., 70, 59-64.
159. Zitoun, D., Bara, L., Basdevant, A., Samama, M. 1996. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dylipidaemias. Arterioscler. Thromb. Vasc. Biol., 16, 77-81.